Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects
jRCT2080221488Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of evacetrapib in dyslipidemia, hyperlipidemia, Hypo-HDL cholesterolemia (HALP) and 1 more (6 arms), sponsored by Eli Lilly and Company. Started Jun 2011; status: recruiting.
02
Drugs
evacetrapib
03
Conditions
dyslipidemiahyperlipidemiaHypo-HDL cholesterolemia (HALP)familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on jRCT2080221488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221488.